Richard Roths Media Announces $52 Million Dollar Investment Approval to Expand its AI-Driven Marketing Systems 
Four Inc. Secures Spot on Washington Technology’s Top 100 Government Contractors List for 11th Consecutive Year 
Tat Hong Equipment Service Co., Ltd. Announces 2025/26 Annual Results Rani Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ
SAN JOSE, Calif., April 25, 2023 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”…
Rani Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ
SAN JOSE, Calif., April 25, 2023 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”…
Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs
PDUFA Date of September 28, 2023 Set for Nyxol® in its First Indication, Reversal of…
Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs
PDUFA Date of September 28, 2023 Set for Nyxol® in its First Indication, Reversal of…
PharmAla Biotech to supply Incannex with GMP LaNeo MDMA and Psilocybin
PharmAla will be the initial supplier for clinical materials in a series of Psychedelic therapy…
PharmAla Biotech to supply Incannex with GMP LaNeo MDMA and Psilocybin
PharmAla will be the initial supplier for clinical materials in a series of Psychedelic therapy…
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meeting
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting…
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meeting
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting…
Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000
All Patients in Three BX1000 Treatment Cohorts Met Criteria for Good or Excellent Intubation Conditions…
Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000
All Patients in Three BX1000 Treatment Cohorts Met Criteria for Good or Excellent Intubation Conditions…
IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma
First-ever orphan drug designation for genetically modified gamma-delta T cell therapies This orphan drug designation…
IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma
First-ever orphan drug designation for genetically modified gamma-delta T cell therapies This orphan drug designation…
Science 37 Appoints SVP, Erica Prowisor, to Bolster Patient Recruitment Velocity, Diversity
New role supports the Company’s objective to lead the industry with faster, more inclusive clinical…
Science 37 Appoints SVP, Erica Prowisor, to Bolster Patient Recruitment Velocity, Diversity
New role supports the Company’s objective to lead the industry with faster, more inclusive clinical…
TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab
SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical…
TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab
SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical…
Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor
WARMINSTER, Pa., April 25, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or…
Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor
WARMINSTER, Pa., April 25, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or…